Core Viewpoint - Wall Street anticipates flat earnings for Zurn Water (ZWS) in the upcoming quarter, with a consensus EPS estimate of $0.29, unchanged from the previous year, while revenues are expected to rise by 2.3% to $382.37 million [1][3]. Earnings Expectations - The stock may experience upward movement if actual earnings exceed expectations in the earnings report scheduled for April 22 [2]. - Conversely, if the earnings report falls short of estimates, the stock could decline [2]. Estimate Revisions - The consensus EPS estimate has been revised 0.08% higher in the last 30 days, indicating a slight bullish sentiment among analysts [4]. - The Zacks Earnings ESP for Zurn Water is +2.34%, suggesting a higher likelihood of beating the consensus EPS estimate [11]. Earnings Surprise Prediction - The Most Accurate Estimate for Zurn Water is above the Zacks Consensus Estimate, indicating recent analyst optimism regarding the company's earnings prospects [10]. - A positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. Historical Performance - Zurn Water has consistently beaten consensus EPS estimates, achieving a surprise of +10.34% in the last reported quarter and surpassing estimates in all four of the last quarters [12][13]. Conclusion - Zurn Water is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings expectations when making investment decisions [16].

Wall Street expects a year-over-year increase in earnings on higher revenues when Enova International (ENVA) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the ...

Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Verizon Communications (VZ) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Range Resources, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - Range Resources is expected to report quarterly earnings of $0.90 per share, reflecting a year-over-year increase of +30.4% [3]. - Revenues are projected to reach $804.12 million, marking a 12% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 6.3% higher in the last 30 days, indicating a reassessment by analysts [4]. - A positive Earnings ESP reading suggests a potential earnings beat, particularly when combined with a strong Zacks Rank [8]. Earnings Surprise Prediction - The Most Accurate Estimate for Range Resources is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.09%, indicating a bearish outlook from analysts [10][11]. - Despite the negative Earnings ESP, the stock holds a Zacks Rank of 2, complicating predictions for an earnings beat [11]. Historical Performance - In the last reported quarter, Range Resources exceeded expectations by delivering earnings of $0.68 per share against an estimate of $0.55, resulting in a surprise of +23.64% [12]. - The company has beaten consensus EPS estimates in all of the last four quarters [13]. Conclusion - While Range Resources may not be a strong candidate for an earnings beat, investors should consider other factors influencing stock performance ahead of the earnings release [16].

The market expects Capital One (COF) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released o ...

Wall Street expects a year-over-year decline in earnings on higher revenues when NVR (NVR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lo ...

Core Viewpoint - Interactive Brokers Group (IBKR) is expected to report strong first-quarter 2025 results, driven by market volatility and increased client activity, with revenue estimates suggesting a 17.6% year-over-year growth [4][5]. Financial Performance - IBKR's fourth-quarter 2024 earnings exceeded the Zacks Consensus Estimate, supported by higher total GAAP net revenues, growth in customer accounts, and an increase in daily average revenue trades (DARTs), although rising expenses posed a challenge [3]. - The consensus estimate for first-quarter revenues is $1.41 billion, indicating a 17.6% increase year-over-year, while earnings are estimated at $1.91, reflecting a 16.5% rise from the previous year [4][5]. - Commission revenues are projected at $502 million, a 32.5% increase from the prior year, while net interest income (NII) is expected to be $813 million, an 8.8% rise [9][10]. Cost and Expense Management - Total operating expenses are anticipated to be elevated, with non-interest expenses expected to reach $409.5 million, marking a 21.5% year-over-year increase [12]. Market Position and Valuation - IBKR's shares are currently trading at a price-to-tangible book (P/TB) ratio of 1.13X, significantly lower than the industry average of 2.46X, indicating a potential buying opportunity [18][21]. - The company has a strong earnings surprise history, having outperformed the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 3.05% [7][9]. Growth Strategy and Innovations - IBKR is expanding its global presence through new product offerings, including Forecast Contracts in Canada and enhanced investment accounts in the U.K. and France [22]. - The company has introduced innovative trading options, such as Overnight Trading and commission-free trading through IBKR Lite, alongside cryptocurrency trading with lower commissions [23]. - Technological advancements and proprietary software development are expected to drive revenue growth, with a compound annual growth rate (CAGR) of 21.8% in net revenues over the past five years [25]. Analyst Sentiment - Positive analyst sentiment suggests that IBKR is well-positioned for growth in a volatile market, with its diversified product offerings and strong technological capabilities enhancing its global reach [27][28].

Company Performance - WaFd reported quarterly earnings of $0.65 per share, exceeding the Zacks Consensus Estimate of $0.60 per share, but down from $0.73 per share a year ago, representing an earnings surprise of 8.33% [1] - The company posted revenues of $179.79 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.38%, compared to year-ago revenues of $171.99 million [2] - Over the last four quarters, WaFd has surpassed consensus EPS estimates three times and topped consensus revenue estimates only once [2] Stock Performance - WaFd shares have declined approximately 24.1% since the beginning of the year, while the S&P 500 has decreased by 10.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $194.36 million, and for the current fiscal year, it is $2.48 on revenues of $755.03 million [7] Industry Outlook - The Zacks Industry Rank for Banks - West is currently in the bottom 46% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Viewpoint - Johnson & Johnson (JNJ) is set to report its first-quarter 2025 results on April 15, with sales and earnings estimates at $21.66 billion and $2.57 per share respectively. The earnings estimates for 2025 and 2026 have seen slight declines over the past 60 days [1]. Group 1: Earnings Performance - JNJ has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 4.43%. The last reported quarter showed a 2.0% earnings surprise [5]. - The company currently has an Earnings ESP of -2.53% and a Zacks Rank of 3 (Hold), indicating a mixed outlook for the upcoming earnings report [6]. Group 2: Sales Estimates and Drivers - Sales in JNJ's Innovative Medicines segment are expected to be driven by strong performances from key products like Darzalex, Tremfya, and Erleada, with respective sales estimates of $3.13 billion, $939.0 million, and $817.0 million [7][8]. - The sales estimate for the Innovative Medicine unit is $13.46 billion, while the MedTech segment is estimated at $8.14 billion, reflecting challenges in year-over-year comparisons [12][14]. Group 3: Competitive Landscape - The launch of biosimilars for Stelara is anticipated to impact its sales significantly, with estimates for Stelara sales at $1.64 billion [9][10]. - The MedTech business is facing headwinds in the Asia Pacific region, particularly in China, due to government cost containment efforts and competitive pressures [13]. Group 4: Strategic Developments - JNJ's diversified business model has been strengthened by the recent acquisition of Intra-Cellular Therapies for approximately $14.6 billion, enhancing its presence in the neurological and psychiatric drug market [24]. - The company is making progress with its pipeline and has been active in mergers and acquisitions, which is expected to bolster growth in its Innovative Medicine segment [23]. Group 5: Legal and Market Sentiment - Ongoing legal battles related to talc lawsuits have created a bearish sentiment around JNJ's stock, with a recent bankruptcy court ruling rejecting its proposed settlement plan [26]. - Despite potential challenges, JNJ has shown steady revenue and EPS growth, suggesting a long-term positive outlook for investors [27].

Core Viewpoint - Citigroup is expected to report first-quarter 2025 results on April 15, 2025, with anticipated increases in both revenue and earnings, despite some concerns regarding deposit balances and net interest income [1][3]. Financial Performance Expectations - The Zacks Consensus Estimate for first-quarter revenues is $21.14 billion, reflecting a year-over-year increase of 0.2% [3]. - The consensus estimate for earnings has been revised downward to $1.84, indicating a 16.5% rise from the prior-year quarter [3]. - Citigroup's net interest income (NII) is estimated at $13.7 billion, suggesting a 1.4% year-over-year rise [8]. Loan and Asset Performance - The average interest-earning assets are pegged at $2.26 trillion, indicating a marginal increase from the prior-year quarter [9]. - The company is likely to have seen a decent rise in loan demand, supported by a stable macroeconomic backdrop [9]. Fee Income and Market Activity - Market revenues are estimated at $5.57 billion, suggesting a 6.9% year-over-year increase [12]. - Income from principal transactions is estimated at $3.54 billion, indicating an 8.2% increase from the prior-year quarter [12]. - Total non-interest income is pegged at $7.54 billion, suggesting a marginal decrease from the prior-year quarter [13]. Expense Management and Investments - Continued investments in technology and risk management are expected to keep the expense base elevated [14]. - The company is undergoing a significant overhaul to enhance performance and reduce costs, including a plan to eliminate 20,000 jobs [26]. Shareholder Returns - Citigroup increased its quarterly dividend by 6% to 56 cents per share in July 2024 [27]. - A $20 billion common stock repurchase program was approved, with plans to repurchase $1.5 billion in the first quarter of 2025 [27]. Valuation Metrics - Citigroup shares gained 1.6% in the first quarter of 2025, outperforming the industry and S&P 500 Index [19]. - The stock is trading at 8.07X forward 12-month earnings, below the industry's forward P/E multiple of 10.59X, indicating an inexpensive valuation compared to peers [20][23]. Strategic Initiatives - The company is streamlining operations to enhance focus on core areas and drive fee-based income growth, projecting a revenue CAGR of 4-5% by 2026-end [24]. - Recent divestitures, including the separation of institutional banking operations in Mexico and the sale of its China-based consumer wealth portfolio, are part of this strategy [24].